Luxacor

Luxacor Brand names, Luxacor Analogs

Luxacor Brand Names Mixture

No information avaliable

Luxacor Chemical_Formula

C₂₀H₂₁ClO₄

Luxacor RX_link

http://www.rxlist.com/cgi/generic3/fenofibrate.htm

Luxacor fda sheet

Luxacor FDA

Luxacor msds (material safety sheet)

Luxacor MSDS

Luxacor Synthesis Reference

No information avaliable

Luxacor Molecular Weight

360.831 g/mol

Luxacor Melting Point

80.5 °C

Luxacor H₂O Solubility

0.25mg/ml at 25 °C

Luxacor State

Solid

Luxacor LogP

5.575

Luxacor Dosage Forms

Capsule; Tablet

Luxacor Indication

For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Luxacor Pharmacology

Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

Luxacor Absorption

Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide

Luxacor side effects and Toxicity

LD₅₀=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.

Luxacor Patient Information